Daily Cardiology Research Analysis
Three impactful cardiology papers stood out today: an RCT-only network meta-analysis suggests Impella may improve 6–12 month survival in myocardial infarction with cardiogenic shock, albeit with higher complications; a patient-level meta-analysis shows combining pretest probability with coronary CT angiography markedly improves obstructive CAD prediction; and a prespecified secondary analysis of EAST-AFNET 4 confirms early rhythm control benefits extend to patients with obesity and diabetes.
Summary
Three impactful cardiology papers stood out today: an RCT-only network meta-analysis suggests Impella may improve 6–12 month survival in myocardial infarction with cardiogenic shock, albeit with higher complications; a patient-level meta-analysis shows combining pretest probability with coronary CT angiography markedly improves obstructive CAD prediction; and a prespecified secondary analysis of EAST-AFNET 4 confirms early rhythm control benefits extend to patients with obesity and diabetes.
Research Themes
- Mechanical circulatory support in cardiogenic shock after myocardial infarction
- Enhancing diagnostic accuracy for obstructive CAD with combined PTP and CTA
- Generalizability of early rhythm control in atrial fibrillation with metabolic comorbidities
Selected Articles
1. Mechanical circulatory support devices vs. standard medical therapy for treatment of myocardial infarction complicated by cardiogenic shock: a network meta-analysis.
Across 18 RCTs (n=1907), Impella reduced 6–12 month mortality versus medical therapy in AMI with cardiogenic shock, but at the cost of higher renal replacement therapy, limb complications, and major bleeding. ECMO and TandemHeart did not confer mortality benefit and increased complications.
Impact: This RCT-only network meta-analysis provides the most rigorous comparative efficacy and safety signal to date for MCS in AMI with shock, suggesting a potential survival advantage with Impella while quantifying trade-offs.
Clinical Implications: For AMI with cardiogenic shock, Impella may be considered when pursuing potential long-term survival benefits, with proactive strategies to mitigate bleeding, limb ischemia, and renal injury. ECMO/TandemHeart decisions should carefully weigh higher vascular/bleeding complications absent clear mortality benefit.
Key Findings
- Impella reduced 6–12 month mortality vs. medical therapy (RR 0.81, P<0.05).
- Impella increased renal replacement therapy (RR 1.6, P=0.02), limb complications (RR 4.8, P=0.02), and major bleeding (RR 2.0, P=0.004).
- ECMO increased vascular complications (RR 3.1, P=0.003) and major bleeding (RR 2.4, P=0.0001), without mortality benefit.
- TandemHeart increased limb complications (RR 19, P=0.05) and showed no mortality advantage.
Methodological Strengths
- Included only randomized controlled trials, reducing confounding and selection bias.
- Network meta-analysis enabling indirect comparisons across multiple MCS devices.
Limitations
- Device generations and management strategies varied across trials, potentially affecting comparability.
- Event rates and RCT sample size remain modest for some devices, limiting precision.
Future Directions: Head-to-head randomized trials of contemporary MCS strategies, standardized anticoagulation/vascular management protocols, and risk-stratified selection criteria are needed to validate survival benefits and minimize harm.
AIMS: Cardiogenic shock (CS) is a common sequitur in acute myocardial infarction (AMI), with significant associated mortality. Mechanical circulatory support (MCS) devices have been used in the management of AMI complicated by CS (AMICS). The relative safety and efficacy of these devices in this context is not yet fully established. Our aim is to provide an up-to-date analysis of outcomes to guide future clinical decisions. METHODS AND RESULTS: We conducted a frequentist network meta-analysis assessing mortality and complications associated with MCS devices, using exclusively randomized controlled trials (RCTs). The devices studied were intra-aortic balloon pump (IABP), Impella®, extracorporeal membrane oxygenation (ECMO), and TandemHeart®. A total of 18 RCTs were identified, with a combined patient population of 1907. Impella® reduced 6-12 month mortality vs. standard medical therapy [risk ratio (RR) 0.81, P < 0.05] but increased requirement for renal replacement therapy, limb complications, and major bleeding (RR, 1.6; P = 0.02; RR, 4.8; P = 0.02; and RR, 2.0; P = 0.004, respectively). No other form of MCS demonstrated a statistically significant mortality benefit when compared with medical therapy; however, ECMO increased vascular complications and major bleeding (RR, 3.1; P = 0.003 and RR, 2.4, P = 0.0001, respectively), and TandemHeart® increased limb complications (RR, 19; P = 0.05). CONCLUSION: Impella® support in AMICS was associated with a long-term survival benefit. Impella®, ECMO, and TandemHeart® use were associated with increased morbidity.
2. Obstructive Coronary Artery Disease Improved Prediction by the COME-CCT Pretest Probability Calculator With Cardiac CT.
Using individual patient data from 5,332 cases, the COME-CCT pretest probability calculator outperformed the Diamond-Forrester model, and integrating this PTP with coronary CTA (AUC 0.86) significantly improved diagnostic accuracy across chest pain subtypes versus either alone.
Impact: This robust IPD meta-analysis provides a practical, generalizable pathway to improve obstructive CAD diagnosis by combining calibrated pretest probability with CTA, informing triage and reducing unnecessary invasive angiography.
Clinical Implications: Adopt calibrated PTP (COME-CCT) and integrate with CTA for stable chest pain evaluation to enhance discrimination, guide downstream testing, and improve net clinical benefit across symptom presentations.
Key Findings
- COME-CCT-PTP outperformed Diamond-Forrester (AUC 0.68 vs 0.63).
- Combining COME-CCT-PTP with CTA achieved AUC 0.86, better than CTA alone (AUC 0.81).
- Decision curve analysis showed higher net benefit across typical, atypical, and nonanginal chest pain.
Methodological Strengths
- Individual patient data meta-analysis across 22 countries with mixed-effects modeling.
- Direct comparison of calibrated PTP, CTA, and their combination with decision curve analysis.
Limitations
- Heterogeneity in CTA acquisition and site practices across studies could influence performance.
- External implementation requires calculator access and local validation.
Future Directions: Prospective implementation studies testing COME-CCT-PTP+CTA pathways on clinical outcomes, cost-effectiveness, and reduction of unnecessary invasive angiography.
BACKGROUND: Combining pretest probability (PTP) with computed tomography angiography (CTA) for diagnosing obstructive coronary artery disease (CAD) has not yet been determined. OBJECTIVES: The purpose of this study was to evaluate the accuracy of PTP calculation alone and with CTA for diagnosing CAD. METHODS: A total of 65 prospective diagnostic accuracy studies of patients clinically referred to invasive coronary angiography with stable chest pain were included in this international collaborative individual patient data Collaborative Meta-Analysis of Cardiac CT (COME-CCT) meta-analysis. Mixed-effects logistic regression with a data set-specific random intercept for clustering was applied to 4 models: the traditional Diamond-Forrester models, a PTP model based on the COME-CCT data (termed COME-CCT-PTP calculator), a CTA alone model, and a combined COME-CCT-PTP with CTA model. RESULTS: Individual patient data from 5,332 patients with clinically indicated invasive coronary angiography from 22 countries were included. The COME-CCT-PTP calculator was more accurate than the original Diamond-Forrester model (AUC: 0.68; 95% CI: 0.66-0.69 vs 0.63; 95% CI: 0.62-0.65). The COME-CCT-PTP with CTA model significantly improved accuracy compared with either model alone (AUC: 0.86; 95% CI: 0.85-0.87 vs 0.81; 95% CI: 0.80-0.82). The improved prediction was consistent in decision curve analysis with an increased net benefit for all chest pain subtypes and was almost equally seen in patients with typical or atypical angina (0.85; 95% CI: 0.84-0.86) and nonanginal or other chest discomfort (0.88; 95% CI: 0.86-0.89). CONCLUSIONS: Combining the COME-CCT-PTP calculator with CTA provides more accurate prediction than the PTP or CTA alone for the diagnosis of obstructive CAD, for all chest pain subtypes.
3. Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.
In a prespecified secondary analysis of EAST-AFNET 4, early rhythm control reduced the composite endpoint similarly regardless of obesity (interaction P=0.22) or diabetes status (interaction P=0.93), with no safety signal differences by diabetes.
Impact: These findings support broad adoption of early rhythm control in AF, addressing concerns about attenuated benefit or harm in patients with obesity or diabetes—two highly prevalent comorbidities.
Clinical Implications: Early rhythm control can be offered to AF patients irrespective of obesity or diabetes, with similar efficacy and safety; comorbid metabolic status alone should not deter rhythm-control strategies.
Key Findings
- No significant interaction of obesity with treatment effect (BMI <30 HR 0.84 vs BMI ≥30 HR 0.69; Pinteraction=0.22).
- No significant interaction of diabetes with treatment effect (diabetes HR 0.77; 95% CI 0.57–1.05 vs no diabetes HR 0.78; 95% CI 0.64–0.96; Pinteraction=0.93).
- Safety outcomes did not differ by diabetes status (interaction P=0.99).
Methodological Strengths
- Prespecified secondary analysis within an RCT framework with blinded outcome assessment.
- Intention-to-treat approach with subgroup interaction testing for obesity and diabetes.
Limitations
- Secondary analysis; not powered primarily for subgroup interactions.
- Open-label treatment assignment may influence care patterns despite blinded outcomes.
Future Directions: Trials testing tailored rhythm-control strategies integrating weight management and diabetes therapies may further augment benefits in metabolically comorbid AF populations.
IMPORTANCE: The EAST-AFNET 4 randomized clinical trial demonstrated that early rhythm control therapy added to anticoagulation therapy and therapy of concomitant conditions reduces the primary composite outcome of cardiovascular death, stroke, hospitalization because of heart failure, or acute coronary syndrome compared to usual care. However, the impact of body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and diabetes on outcomes in EAST-AFNET 4 is not known. OBJECTIVE: To assess the effects of BMI and diabetes on outcomes in EAST-AFNET 4. DESIGN, SETTING, AND PARTICIPANTS: EAST-AFNET 4 is an international, investigator-initiated, parallel-group, open, blinded outcome assessment randomized clinical trial conducted in 11 European countries. Patients who had early atrial fibrillation (AF, diagnosed ≤1 year before enrollment) and cardiovascular conditions were eligible for inclusion. The current analysis is a prespecified secondary analysis of the EAST-AFNET 4 trial performed in the final, locked dataset assigning patients to therapy group on the basis of randomization (intention-to-treat population). EAST-AFNET 4 was conducted from June 2010 to May 2020, and this secondary analysis of the final locked data base was performed in 2024. INTERVENTION: EAST-AFNET 4 randomly assigned patients to either early rhythm control or usual care. MAIN OUTCOMES AND MEASURE: The primary outcome of this analysis and the EAST-AFNET 4 trial is a composite of cardiovascular death, stroke, hospitalization because of heart failure, or acute coronary syndrome. RESULTS: There were 1086 patients with obesity (BMI ≥30; mean [SD] BMI 34.5 [4.2]) and 1690 patients without obesity (BMI <30; mean [SD] BMI 25.9 [2.6]). Overall mean patient age was 70 years, and 1293 patients (46.6%) were female. Patients with obesity were younger (mean [SD] age, 68 [8.6] vs 72 [7.7] years) and had more frequently nonparoxysmal AF patterns (31% vs 24%) than patients without obesity. There was no difference in mean (SD) CHA2DS2-VASc score (3.4 [1.3] vs 3.3 [1.3]). Obesity did not change the effect of early rhythm control therapy on the first primary outcome (hazard rate point estimates: BMI <30, 0.84; BMI ≥30, 0.69; P for interaction = .22). Patients with diabetes were younger (mean [SD] age, 69 [8.6] vs 71 [8.2] years; P = .001) and had a higher mean CHA2DS2-VASC score (4.06 vs 3.11; P < .001). Diabetes did not interact with the treatment effect of early rhythm control (diabetes: hazard ratio [HR], 0.77; 95% CI, 0.57-1.05 vs no diabetes: HR, 0.78; 95% CI, 0.64-0.96; P for interaction = .93). There was no difference in safety outcomes between patients with and without diabetes (64 of 351 patients [18.2%] vs 167 of 1039 patients [16.1%]; P for interaction = .99). CONCLUSIONS AND RELEVANCE: This secondary analysis of the EAST-AFNET 4 randomized clinical trial shows that early rhythm control therapy retains its effectiveness and safety in patients with and without diabetes and patients with and without obesity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01288352.